Key Takeaways ELV is set to report Q2 earnings of $9.20 per share on$48.13B in revenues, which is up 11.4% YoY. Product and premium revenues, along with CarelonRx growth, are expected to support Q2 top-line gains. Higher benefit expenses and interest expenses may weigh on margins, with costs up nearly 11% YoY.Elevance Health, Inc. (ELV) is set to report its second-quarter 2025 results on July 17, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is curr ...